08:56 AM EDT, 09/07/2026 (MT Newswires) -- BofA Global Research noted that AstraZeneca (AZN.L, AZN.ST) securing approval for its breast cancer drug camizestrant in the US based on the Serena-6 phase 3 trial results came as a "positive surprise" following the previous "negative" decision of an advisory committee of the US Food and Drug Administration. AstraZeneca said Sept. 4 that the drug, branded Etcamah, in combination with a cyclin-dependent kinase 4/6 inhibitor, secured approval in the US for the treatment of adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of the ESR1 mutation. "We view [the Serena-6 approval] as a c$1bn opp., which could be larger should SERENA-4 fail (data imminent and debates on potential success described below) and there be no true [first-line] products approved (also [Roche's] persevERA fail). That said, our positive view of camizestrant is mostly driven by our bullish view of CAMBRIA-1 (adjuvant switch study due 2H27E), which we see high probability and anchor asset to our Bull thesis," analysts said Monday. "Of our c$7.5bn peak camizestrant sales, we attribute c$4bn to adjuvant trials (CAMBRIA-1/2), a larger opp vs 1L, and could be bigger given size of adjuvant market. SERENA-6 approval now covers a portion of cons c$3bn peak, with upside to cons on CAMBRIA success independent of SERENA-4." The research firm also highlighted the pharmaceutical company's "attractive" valuation amid a busy pipeline for the remainder of 2026 and in 2027, with key upcoming data readouts including the Serena-4 trial for camizestrant in first-line metastatic breast cancer and Avanzar study for datopotamab deruxtecan in first-line non-small cell lung cancer. The buy rating on the London-listed stock was reiterated, with a price objective of 165 pounds sterling.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.